Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Although metastatic breast cancer (BC) is unlikely to be cured, there have been meaningful improvements in survival due to the increasing availability of more effective systemic therapies, including both endocrine backbones as well as targeted agents. Hormone receptor positive (HR+) Human epidermal growth factor receptor 2 negative (HER2-) BC accounts for almost two thirds of BC diagnoses, and inhibiting estrogen receptor (ER) signaling with endocrine therapies (ETs) still represents the mainstay of the treatment for this subtype, in both early and advanced settings [1].

Source: Cancer Treatment Reviews - April 27, 2023 Category: Cancer & Oncology Authors: Chiara Corti, Carmine De Angelis, Giampaolo Bianchini, Luca Malorni, Mario Giuliano, Erika Hamilton, Rinath Jeselsohn, Komal Jhaveri, Giuseppe Curigliano, Carmen Criscitiello Tags: New Drugs Source Type: research